Platelet-Derived Mediators in Hospitalized COVID-19 Patients with 60-Day Outcomes

245 hospitalized COVID-19 patients had plasma levels of eight platelet-derived mediators measured. The data, authored by Kari Otterdal and shared on figshare, examines associations with respiratory failure, ICU admittance, and 60-day mortality. A subpopulation was also followed up at three, six, and twelve months post-hospitalization.

Use Cases

• Predicting ICU admission or respiratory failure risk based on P-selectin levels.
• Modeling 60-day mortality risk based on levels of PF4/CXCL4, ENA-78/CXCL5, and NAP-2/CXCL7.
• Analyzing long-term platelet activation by tracking sCD40L, ENA-78/CXCL7, and VEGF-A levels up to 12 months post-hospitalization.
• Investigating in vitro platelet response to SARS-CoV-2 based on mediator release patterns.

Strengths

• Includes longitudinal data for a subpopulation with measurements at three, six, and twelve months post-hospitalization.
• Focuses on eight specific platelet-derived mediators (e.g., RANTES, P-selectin, VEGF-A) with clear clinical outcomes defined.
• Data is associated with a peer-reviewed study methodology described in the background and methods.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (34.3 KB), indicating limited scope.

Provenance

Source

figshare, author Kari Otterdal.

Collection Method

Plasma levels of mediators were measured in patient cohorts and in vitro experiments with isolated platelets.

Time Range

Covers hospitalization period and follow-up up to 12 months post-discharge.

Freshness

Last updated 2026-03-17 13:04:46; freshness should be verified.